150407-69-5 Usage
General Description
(S)-N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is a synthetic chemical compound which involves multiple functional groups. The "BOC" part refers to a tert-butyloxycarbonyl group which is a protective group used in most organic synthesis for amines. The "CBZ" indicates a Carboxybenzyl group, another protective group used commonly in organic chemistry for protection of amines. The "2-PIPERAZINE" part of the name suggests a piperazine ring structure, a class of organic compounds containing a six-membered ring with two nitrogen atoms at opposite positions in the ring. Lastly, "CARBOXYLIC ACID" describes a functional group consisting of a carbonyl(C=O) and hydroxyl(O-H) group attached to the same carbon atom. The specific properties and applications of this compound can vary widely depending on its further modification and usage in synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 150407-69-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,0,4,0 and 7 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 150407-69:
(8*1)+(7*5)+(6*0)+(5*4)+(4*0)+(3*7)+(2*6)+(1*9)=105
105 % 10 = 5
So 150407-69-5 is a valid CAS Registry Number.
InChI:InChI=1/C18H24N2O6/c1-18(2,3)26-16(23)19-9-10-20(14(11-19)15(21)22)17(24)25-12-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3,(H,21,22)/t14-/m0/s1
150407-69-5Relevant articles and documents
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00276, (2017/07/04)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.
THROMBIN INHIBITORS
-
Page/Page column 29; 30, (2013/10/21)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: (I) or a pharmaceutically acceptable salt thereof, wherein Q is CH2, NR4, O, S, S(O) or S(O2
Disubstituted pyrimidines as Lck inhibitors
Hunt, Julianne A.,Beresis, Richard T.,Goulet, Joung L.,Holmes, Mark A.,Hong, Xinfang J.,Kovacs, Ernest,Mills, Sander G.,Ruzek, Rowena D.,Wong, Frederick,Hermes, Jeffrey D.,Park, Young-Whan,Salowe, Scott P.,Sonatore, Lisa M.,Wu, Lin,Woods, Andrea,Zaller, Dennis M.,Sinclair, Peter J.
supporting information; scheme or table, p. 5440 - 5443 (2010/04/26)
We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cell
